Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδ T cells: a phase I clinical study
M Sakamoto, J Nakajima, T Murakawa… - Journal of …, 2011 - journals.lww.com
Human γδ T cells can recognize and kill non-small cell lung cancer (NSCLC) cells using the
Vγ9Vδ2 T-cell receptor and/or NKG2D. We have established clinical grade large-scale ex
vivo expansion of γδ T cells from peripheral blood mononuclear cells by culturing with
zoledronate and interleukin-2 (IL-2). A phase I study was conducted to evaluate safety and
potential antitumor effects of re-infusing ex vivo expanded γδ T cells in patients with
recurrent or advanced NSCLC. Patient's peripheral blood mononuclear cells were …
Vγ9Vδ2 T-cell receptor and/or NKG2D. We have established clinical grade large-scale ex
vivo expansion of γδ T cells from peripheral blood mononuclear cells by culturing with
zoledronate and interleukin-2 (IL-2). A phase I study was conducted to evaluate safety and
potential antitumor effects of re-infusing ex vivo expanded γδ T cells in patients with
recurrent or advanced NSCLC. Patient's peripheral blood mononuclear cells were …